GlassScriptPhysician profile
Angela Chung
NPI 1326569419
$2,421.21
in general payments reported to CMS, 2019-2025
24 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.86 · 2020: $126 · 2021: $579 · 2022: $925 · 2023: $619 · 2024: $140 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.64 | 2020-2024 | Ubrelvy |
| Lilly USA, LLC | $236.37 | 2021-2023 | Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.23 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $210.87 | 2021-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $178.41 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $163.64 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $133.64 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $114.17 | 2020-2021 | |
| Abbott Laboratories | $107.07 | 2022 | |
| Exact Sciences Corporation | $102.38 | 2023-2024 | Cologuard Collection Kit |
| Mannkind Corporation | $99.84 | 2023 | Afrezza |
| Janssen Pharmaceuticals, INC | $98.68 | 2021 | |
| Glaxosmithkline, LLC. | $68.25 | 2023-2025 | Shingrix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $68.08 | 2021-2023 | Trintellix |
| Pfizer INC. | $52.58 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $43.65 | 2022 | |
| Nestle Healthcare Nutrition INC. | $26.66 | 2022 | |
| Sobi, INC | $23.27 | 2023 | |
| Dexcom, INC. | $21.96 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $20.47 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.39 | 2023 | Horizant |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2021 | |
| Genentech USA, INC. | $13.10 | 2021 | |
| Edwards Lifesciences Corporation | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.